Late-stage oncology capacity expansion is underscored by Radiance Biopharma’s signing of a multi-billion-dollar licensing agreement with China-based Novatim Immune Therapeutics. The pact grants Radiance global rights excluding select Asian markets for a bispecific nanobody antibody-drug conjugate (ADC) targeting c-MET and EGFR receptors to treat solid tumors. Currently in phase I trials in China with recent U.S. IND clearance, the deal includes a $15 million upfront payment, milestone payments up to $1.165 billion, and tiered royalties, reflecting the potential commercial impact of this novel therapeutic approach.